OROPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for OROPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OROPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for OROPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Peptide vaccine shows promise in head and neck cancer trial, but study halted early
Disease control TerminatedThis study tested a peptide-based immunotherapy given before surgery to people with head and neck cancer. The goal was to see if the vaccine could boost the immune system to fight the tumor. Only 17 people took part before the study was stopped early. The main focus was on safety…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
Promising combo for advanced cancers hits snag: trial terminated early
Disease control TerminatedThis study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:50 UTC